Roche Holding AG's third-quarter sales increased by 9% to 15.1 billion Swiss francs ($17.5 billion), exceeding analysts' expectations of 14.9 billion francs.
The growth was driven by the strong performance of its eye drug Vabysmo, as well as treatments for cancer, hemophilia, and multiple sclerosis.
The company's successful expansion of its drug portfolio demonstrates its commitment to innovation in the healthcare sector. This positive financial performance confirms Roche's position as a major player in the global pharmaceutical market.